Evolving concepts on benefits and risks associated with therapeutic strategies to raise HDL

Current Opinion in Cardiology

Volumn 25, Issue 6, 2010, Pages 603-608

  Shah, Prediman K ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

apo A 1; HDL; inflammation; reverse cholesterol transport

Indexed keywords

ANACETRAPIB; ANTICOAGULANT AGENT; ANTIINFLAMMATORY AGENT; APOLIPOPROTEIN A1; APP 018; ARYLDIALKYLPHOSPHATASE; ATI 5261; ATORVASTATIN; ATROMID; CHOLESTEROL ESTER TRANSFER PROTEIN; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; CSL 111; DALCETRAPIB; ENDOTHELIAL LIPASE; ETC 216; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOMODULATING AGENT; LOW DENSITY LIPOPROTEIN; NICOTINIC ACID; PLACEBO; PROTECTIVE AGENT; RVX 208; SMALL MOLECULE TRANSPORT AGENT; TORCETRAPIB; TRIACYLGLYCEROL LIPASE; UNCLASSIFIED DRUG;

ARTERY THROMBOSIS; ATHEROGENESIS; ATHEROSCLEROSIS; BIOLOGICAL ACTIVITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR SYMPTOM; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG FATALITY; DRUG WITHDRAWAL; ENDOTHELIAL DYSFUNCTION; GASTROINTESTINAL SYMPTOM; GENE TRANSFER; HEART PROTECTION; HUMAN; IMMUNOMODULATION; LIVER TOXICITY; METABOLISM; MUSCULOSKELETAL DISEASE; NONHUMAN; PANCREAS ISLET BETA CELL; PARTICLE SIZE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SINGLE DRUG DOSE; SKIN IRRITATION;

ANTICHOLESTEREMIC AGENTS; APOLIPOPROTEIN A-I; CHOLESTEROL, LDL; CORONARY ARTERY DISEASE; DYSLIPIDEMIAS; ENDOTHELIUM, VASCULAR; FIBRIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPID METABOLISM; PARTICLE SIZE; PATIENT CARE PLANNING; RISK ASSESSMENT; RISK FACTORS;

EID: 78049309897     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/HCO.0b013e32833f0382     Document Type: Review

References (48)

1. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366:1267-1278.
2. Barter P, Gotto AM, La Rosa JC, et al., Treating to New Targets Investigators. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 2007; 357:1301-1310.
3. Hausenloy DJ, Yellon DM. Enhancing cardiovascular disease risk reduction: raising high density lipoprotein levels. Curr Opin Cardol 2009; 24:473-482.
4. Shah PK. High-density lipoprotein mimetics: focus on synthetic high-density lipoprotein. Am J Cardiol 2007; 100 (11A):S62-S67.
5. Shah PK. Emerging HDL-based therapies for atherothrombotic vascular disease. Curr Treat Options Cardiovasc Med 2007; 9:60-70. (Pubitemid 46578390)
6. Khera AV, Rader DJ. Future therapeutic directions in reverse cholesterol transport. Curr Atheroscler Rep 2010; 12:73-81.
7. Phillipis MC, Rothblat GH. High density lipoprotein heterogeneity and function in reverse cholesterol transport. Curr Opin Lipidol 2010; 21:229-238.
8. Yvan-Charvet L, Welch C, Pagler TA, et al. Increased inflammatory gene expression in ABC transporter deficient macrophages: free cholesterol accumulation, increased signaling via toll-like receptors and neutrophil infiltration of atherosclerotic lesions. Circulation 2008; 118:1837-1847.
9. Tang C, Liu Y, Kessler PS, et al. The macrophage cholesterol exporter ABCA1 functions as an anti-inflammatory receptor. J Biol Chem 2009; 284:32336-32343.
10. Zhu X, Lee JY, Timmins JM, et al. Increased cellular free cholesterol in macrophage specific ABCA1 knockout mice enhances pro-inflammatory response of macrophages. J Biol Chem 2008; 283:22930-22941.
11. Murphy AJ, Woollard KJ, Hoang A, et al. High density lipoprotein reduces the human monocyte inflammatory response. Arterioscler Thromb Vasc Biol 2008; 28:2071-2077.
12. Wang SH, Yuan SG, Peng DQ, Zhao SP. High density lipoprotein affects antigen presentation by interfering with lipid raft: A promising antiatherogenic strategy. Clin Exp Immunol 2010; 160:137-142.
13. Wilhelm AJ, Zabalawi M, Grayson JM, et al. Apolipoprotein A-1 and its role in lymphocyte cholesterol homeostasis and autoimmunity. Arterioscler Thromb Vasc Biol 2009; 29:843-849.
14. Llodrá J, Angeli V, Liu J, et al. Emigration of monocyte-derived cells from atherosclerotic lesions characterizes regressive, but not progressive, plaques. Proc Natl Acad Sci USA 2004; 101:11779-11784. (Pubitemid 39095371)
15. McGillicuddy FC, de la Llera Moya M, Hinkle CC, et al. Inflammation impairs reverse cholesterol transport in vivo. Circulation 2009; 119:1135-1145.
16. Yvan-Charvet L, Pagler T, Gautier EL, et al. ATP-binding cassette transporters and HDL suppress hematopoetic stem cell proliferation. Science 2010; 328:1689-1693.
17. Navab M, Yu R, Gharavi N, et al. High-density lipoprotein: antioxidant and anti-inflammatory properties. Curr Atheroscler Rep 2007; 9:244-248; Review. (Pubitemid 47629072)
18. Zhang Q, Liu L, Zheng XY. Protective roles of HDL, apo A-I and mimetic peptide on endothelial function: through endothelial cells and endothelial progenitor cells. Int J Cardiol 2009; 133:286-292.
19. Oslakovic C, Krisinger MJ, Andersson A, et al. Anionic phospholipids lose their procoagulant properties when incorporated into high density lipoproteins. J Biol Chem 2009; 284:5896-5904.
20. Kruit JK, Brunhma LR, Verchere CB, Hayden MR. HDL and LDL cholesterol significantly influence beta cell function in type-2 diabetes. Curr Opin Lipidol 2010; 21:178-185.
21. Navab M, Reddy ST, Van Lenten BJ, et al. The role of dysfunctional HDL in atherosclerosis. J Lipid Res 2009; 50:S145-S149.
22. Heinecke JW. The HDL proteome: A marker-and perhaps mediator-of coronary artery disease. J Lipid Res 2009; 50:S167-S171.
23. Birjmohun RS, Hutten BA, Kastelein JJ, et al. Efficacy and safety of high-density lipoprotein cholesterol increasing compounds-a meta-analysis of randomized controlled trials. J Am Coll Cardiol 2005; 45:185-197. (Pubitemid 40094724)
24. Kamanna VS, Ganji SH, Kashyap ML. Niacin: an old drug rejuvenated. Curr Atheroscler Rep 2009; 11:45-51.
25. Hussein AA, Nicholls SJ. Critical appraisal of laropiprant and extended-release niacin combination in the management of mixed dyslipidemias and primary hypercholesterolemia. Ther Clin Risk Manag 2010; 6:183-190.
26. Shah PK. The yin and yang of cholesteryl ester transfer protein in cardiovascular disease. Circulation 2009; 120:2408-2410.
27. Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007; 357:2109-2122. (Pubitemid 350146106)
28. Nissen SE, Tardif JC, Nicholls SJ, et al. Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med 2007; 356:1304-1316. (Pubitemid 46513296)
29. Kastelein JJ, van Leuven SI, Burgess L, et al. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med 2007; 356:1620-1630. (Pubitemid 46631671)
30. Schwartz GG, Olsson AG, Ballantyne CM, et al., dal-OUTCOMES Committees and Investigators. Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome. Am Heart J 2009; 158:896.e3-901.e3.
31. Cannon CP, Dansky HM, Davidson M, et al., DEFINE investigators. Design of the DEFINE trial: determining the EFficacy and tolerability of CETP INhibition with Anac Etrapib. Am Heart J 2009; 158:513.e3-519.e3.
32. Bailey D, Jahagirdar R, Gordon A, et al. RVX-208: A small molecule that increases apolipoprotein A-I and high-density lipoprotein cholesterol in vitro and in vivo. J Am Coll Cardiol 2010; 55:2580-2589.
33. Waksman R, Torguson R, Kent KM, et al. A first-in-man, randomized, placebo-controlled study to evaluate the safety and feasibility of autologous delipidated high-density lipoprotein plasma infusions in patients with acute coronary syndrome. J Am Coll Cardiol 2010; 55:2727-2735.
34. Getz GS, Wool GD, Reardon C. Biological properties of apolipoprotein mimetic peptides. Curr Atheroscler Rep 2010; 12:96-104.
35. Bloedon LT, Dunbar R, Duffy D, et al. Safety, pharmacokinetics, and phar-macodynamics of oral apo A-I mimetic peptide D-4F in high-risk cardiovascular patients. J Lipid Res 2008; 49:1344-1352.
36. Bielicki JK, Zhang H, Cortez Y, et al. A new HDL mimetic peptide that stimulates cellular cholesterol efflux with high efficiency greatly reduces atherosclerosis in mice. J Lipid Res 2010; 51:1496-1503.
37. Nissen SE, Tsunoda T, Tuzcu EM, et al. Effect of recombinant Apo A-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: A randomized controlled trial. JAMA 2003; 290:2292-2300. (Pubitemid 37430562)
38. Chyu KY, Yano J, Li X, et al. Safflower seed-derived DES-1,2-Apo A1 Milano reduces atherosclerosis in hypercholesterolemic apolipoprotein E-/-mice. J Am Coll Cardiol 2010; 55:A50.E478.
39. Wang L, Sharifi BG, Pan T, et al. Bone marrow transplantation shows superior atheroprotective effects of gene therapy with apolipoprotein A-I Milano compared with wild-type apolipoprotein A-I in hyperlipidemic mice. J Am Coll Cardiol 2006; 48:1459-1468. (Pubitemid 44468006)
40. de la Llera-Moya M, Drazul-Schrader D, Asztalos BF, et al. The ability to promote efflux via ABCA1 determines the capacity of serum specimens with similar high-density lipoprotein cholesterol to remove cholesterol from macrophages. Arterioscler Thromb Vasc Biol 2010; 30:796-801.
41. Tardif JC, Gré goire J, L'Allier PL, et al. Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: A randomized controlled trial. JAMA 2007; 297:1675-1682. (Pubitemid 46631626)
42. Shaw JA, Bobik A, Murphy A, et al. Infusion of reconstituted high-density lipoprotein leads to acute changes in human atherosclerotic plaque. Circ Res 2008; 103:1084-1091.
43. Jaye M, Lynch KJ, Krawiec J, et al. A novel endothelial-derived lipase that modulates HDL metabolism. Nat Genet 1999; 21:424-428. (Pubitemid 29159582)
44. Edmondson AC, Brown RJ, Kathiresan S, et al. Loss-of-function variants in endothelial lipase are a cause of elevated HDL cholesterol in humans. J Clin Invest 2009; 119:1042-1050.
45. Goodman KB, Bury MJ, Cheung M, et al. Discovery of potent, selective sulfonylfuran urea endothelial lipase inhibitors. Bioorg Med Chem Lett 2009; 19:27-30.
46. Van Craeyveld E, Gordts S, Jacobs F, De Geest B. Gene therapy to improve high-density lipoprotein metabolism and function. Curr Pharm Des 2010; 16:1531-1544.
47. Tian F, Wang L, Yang M, et al. Comparative Antiatherogenic Effects of a Single Intravenous Injection of r AAV8 or r AAV2 Encoding Apo A-I Milano Gene. Circulation 2009; 120:S1017-S1018.
48. Asokan A. Reengineered AAV vectors: old dog, new tricks. Discov Med 2010; 9:399-403.